High content screening (HCS) is widely used in drug discovery and cell biology in life sciences research. Currently, high content screening is widely used for primary and secondary screening, target identification and validation, toxicity studies, and compound profiling. In this article, we will take a look at the commercial viability and future growth of these applications.
High Content Screening in Primary & Secondary Screening
High content screening is an effective mechanism of processing cells at early stages of the drug discovery process. Innovation in HCS technology has meant that it is now being used for primary as well as secondary screening. This is especially true in case of diseases with unknown causative molecular targets.
Pharmaceutical companies around the world are more focused on assaying project-related, compound libraries. Owing to these changes, application of high content screening in primary and secondary screening is anticipated to witness a steady increase. Use of HCS in primary and secondary screen is anticipated to acquire a market share of 36.6% by 2025.
High Content Screening in Target Identification & Validation
HCS has proved to be highly successful in identify new components of cells and validating their functionalities. Target identification and validation provides a base through which molecules that interfere with disease can be identified. High content screening has the advantage of providing spatial information about cells during the target identification and validation process. Use of high content screening for target identification and validation is estimated to reach US$ 563 Mn by 2025.
High Content Screening in Toxicity Studies
High content screening allows researchers to analyse the behaviour of multiple cells and measure their response to environmental and chemical stimuli. Although HCS has gained reliability in the field of cytotoxicity, however evaluation of cells beyond this remains a key opportunity for HCS globally. Toxicity studies using high content screening, as an application segment, was worth US$ 205.2 Mn in 2015, and according to a research report by Future Market Insights, this segment will witness a compound annual growth rate of 6.3% till 2025.
High Content Screening in Compound Profiling
The use of high content screening in compound profiling is anticipated to grow in the near future. HCS offers researchers numerous advantages in compound profiling over traditional image-based assays. It is anticipated that the market value of compound profiling segment will be to the tune of US$ 240.5 Mn.
Key Trends in High Content Screening Sector
Secondary screening is gaining focus among researchers and pharmaceutical companies. Growing concerns related to toxicity studies and emphasis on providing solutions in hepatoxicity is expected to increase the demand for HCS instruments in the near future.
Development of value-added applications has emerged as a key trend in the high content screening industry, with only a select few pharmaceutical companies developing a specific product line for life sciences.
High price of HCS instruments drives the demand for other image analysis instruments, such as flow cytometers. However, innovation in the field of manufacturing technology and reduction in the price of HCS components is expected to bring down the prices in the near future.
The positive impact of high content screening instruments on toxicity studies has resulted in increased adoption of this technology by pharmaceutical companies. For example, Genedata AG’s 75% image analysis and management software customers are pharmaceutical companies.
Increase in the development of automated systems to analyse cell separation and scalability is currently being witnessed in the sector. Demand for efficient purification protocols is expected to boost the demand for high content screening instruments in the future.
Browse Full "High Content Screening (HCS) Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025" Market Research Report at http://www.futuremarketinsights.com/reports/details/high-content-screening-market
The Freeze Thaw System Market is segmented by Product Type (freeze-thaw modular platforms, controlled rate chambers, single-use bags, and shippers), Application (R&D, pre-clinical & clinical, and commercial), End User (academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and contract manufacturing organizations), and Region. Forecast for 2026 to 2036.
The Compounding Pharmacies Market is segmented by Product (oral medication, topical medication, mouthwashes, and suppositories), Application (medication for adults, medication for veterinary, medication for children, and medication for geriatric), Therapeutic Area (pain management, hormone replacement therapy, and others), and Region. Forecast for 2026 to 2036.
The Urban Pharma Micro-Depot and Delivery Network market is segmented by network model (dark-store depots, partner pharmacies, hospital satellites, hybrid hubs), delivery speed (same-day, two-hour, scheduled, next-day), temperature band (ambient, cold chain, controlled room), order type (chronic refills, acute Rx, OTC add-ons, specialty Rx), end user (retail chains, digital pharmacies, hospitals, clinic groups), and Region. Forecast for 2026 to 2036.
The high-value healthcare asset tracking and recovery platforms market is segmented by Technology (BLE, RFID, UWB, Wi-Fi), Deployment (Cloud, Hybrid, On-premise), Asset Class (Infusion pumps, Ventilators, Monitors, Wheelchairs, Imaging carts), End User (Hospitals, Health systems, ASCs, Clinics), Component (Software, Tags, Readers, Services), and Region. Forecast for 2026 to 2036.
The Post-Acute Transition Care Coordination Platform Market Is Segmented By Deployment (Cloud, On-Premise, Hybrid), Module (Referral Management, Discharge Planning, Network Management, Authorization, Analytics), Care-Setting (Hospitals, SNFs, Home Health, Rehab Centers, ACOs), End User (Providers, Payers, Health Systems, Community Networks), Transition Type (Hospital-To-SNF, Hospital-To-Home, Hospital-To-Rehab, SNF-To-Home, Cross-Setting Follow-Up), And Region. Forecast For 2026 To 2036.
